JP2014530878A - 癌治療のための治療用組合せ - Google Patents
癌治療のための治療用組合せ Download PDFInfo
- Publication number
- JP2014530878A JP2014530878A JP2014537346A JP2014537346A JP2014530878A JP 2014530878 A JP2014530878 A JP 2014530878A JP 2014537346 A JP2014537346 A JP 2014537346A JP 2014537346 A JP2014537346 A JP 2014537346A JP 2014530878 A JP2014530878 A JP 2014530878A
- Authority
- JP
- Japan
- Prior art keywords
- oleander
- therapeutic combination
- cisplatin
- extract
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
驚くべきことに、白金を含む抗腫瘍剤とキョウチクトウ属の種からの抽出物との組合せが相乗的に増大した抗腫瘍活性を示すことが見いだされた。その結果として、前記白金系抗腫瘍剤の別の方法では効果がないが良好な耐容性を示す用量が、それ自体では効果のない抽出物の投与量と組み合わされた場合に、臨床的に有用な抗腫瘍効果を及ぼす。
互いに補足する3種の異なる生存率アッセイを選択し、濃度および細胞株に依存する結果を得た。3種のアッセイは、メチルテトラゾリウム色素アッセイ、スルホローダミンB蛍光色素アッセイ、およびクリスタルバイオレット色素アッセイである。
ヒト癌細胞株は、European Collection of Cell CulturesによりHealth Protective Agency, UKから入手し、ヒト前立腺癌(PC3、LNCaPおよび22Rv1)、ヒト乳癌(MDA-MB 231、T47D、MCF-7)、非小細胞肺癌(CALU-1、COLO699N、COR-L 105)、大腸癌(HCT-116、HT55、HCT-15)、黒色腫(A375)、および膵臓癌(PANC-1)に由来する株が含まれた。
各細胞株に対してすべての処理を3回繰り返しておこなった。すべての効果の統計的有意性は、「平均値の差」の検定(p < 0.05)により評価した。
下記の表1は、細胞集団密度を吸光度データから推定した、前立腺癌由来細胞株であるLNCaP細胞を用いて得られた結果を示す。
下記の表2は、細胞集団密度を吸光度データから推定した、黒色腫由来細胞株であるA375細胞を用いて得られた結果を示す。
下記の表3は、細胞集団密度を吸光度データから推定した、膵臓癌由来細胞株であるPANC-1細胞を用いて得られた結果を示す。
下記の表4は、細胞集団密度を吸光度データから推定した、肺癌由来細胞株であるCOLO699N細胞を用いて得られた結果を示す。
Claims (25)
- (I)白金を含む抗腫瘍剤および(II)キョウチクトウ属の種からの抽出物を含む治療用組合せ。
- (I)が、(II)の非存在下で抗腫瘍活性の増加をもたらす効果を有する量で存在する、請求項1に記載の治療用組合せ。
- (I)が、(II)の非存在下で抗腫瘍活性の増加をもたらす効果がない量で存在する、請求項1に記載の治療用組合せ。
- (I)がシスプラチン、カルボプラチン、オキサリプラチン、サトラプラチン、ピコプラチン、ネダプラチン、トリプラチン、およびホスファプラチンからなる群より選択される、請求項1に記載の治療用組合せ。
- (I)がシスプラチンである、請求項1に記載の治療用組合せ。
- (II)がキョウチクトウ(ネリウム・インディクム(Nerium indicum))、セイヨウキョウチクトウ(ネリウム・オレアンデル(Nerium oleander))、およびキョウチクトウ(ネリウム・オドルム(Nerium odorum))からなる群より選択される種からの抽出物である、請求項1に記載の治療用組合せ。
- (II)がセイヨウキョウチクトウ種からの抽出物である、請求項1に記載の治療用組合せ。
- (II)が水性抽出物である、請求項1に記載の治療用組合せ。
- (II)がアロエをベースとする抽出物である、請求項1に記載の治療用組合せ。
- (I)がシスプラチンであり、(II)がセイヨウキョウチクトウ種からの抽出物である、請求項1に記載の治療用組合せ。
- (I)と(II)とが別々の製剤として存在する、請求項1に記載の治療用組合せ。
- 癌治療を必要とする患者に、治療的有効量の請求項1に記載の治療用組合せを投与することを含む、癌を治療する方法。
- (I)が、(II)の非存在下で抗腫瘍活性の増加をもたらす効果を有する量で存在する、請求項12に記載の方法。
- (I)が、(II)の非存在下で抗腫瘍活性の増加をもたらす効果がない量で存在する、請求項12に記載の方法。
- (I)がシスプラチン、カルボプラチン、オキサリプラチン、サトラプラチン、ピコプラチン、ネダプラチン、トリプラチン、およびホスファプラチンからなる群より選択される、請求項12に記載の方法。
- (I)がシスプラチンである、請求項12に記載の方法。
- (II)がキョウチクトウ(Nerium indicum)、セイヨウキョウチクトウ(Nerium oleander)、およびキョウチクトウ(Nerium odorum)からなる群より選択される種からの抽出物である、請求項12に記載の方法。
- (II)がセイヨウキョウチクトウ種からの抽出物である、請求項12に記載の方法。
- (II)が水性抽出物である、請求項12に記載の方法。
- (II)がアロエをベースとする抽出物である、請求項12に記載の方法。
- (I)がシスプラチンであり、(II)がセイヨウキョウチクトウ種からの抽出物である、請求項12に記載の方法。
- 前記治療用組合せの(I)および(II)が、同時に、別々に、または連続的に患者に投与される、請求項12に記載の方法。
- (II)が患者に筋肉内投与、舌下投与、または筋肉内および舌下投与される、請求項12に記載の方法。
- (II)が患者に2回以上の投与で舌下投与される、請求項12に記載の方法。
- 治療される癌が前立腺癌、黒色腫、膵臓癌、肺癌、乳癌、または大腸癌である、請求項12に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161549386P | 2011-10-20 | 2011-10-20 | |
US61/549,386 | 2011-10-20 | ||
PCT/US2012/061226 WO2013059753A1 (en) | 2011-10-20 | 2012-10-20 | Therapeutic combination for the treatment of cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014530878A true JP2014530878A (ja) | 2014-11-20 |
JP6255346B2 JP6255346B2 (ja) | 2017-12-27 |
Family
ID=48141445
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014537346A Expired - Fee Related JP6255346B2 (ja) | 2011-10-20 | 2012-10-20 | 癌治療のための治療用組合せ |
Country Status (13)
Country | Link |
---|---|
US (2) | US20130209579A1 (ja) |
EP (2) | EP3711754A1 (ja) |
JP (1) | JP6255346B2 (ja) |
CN (2) | CN104093405A (ja) |
AU (3) | AU2012325819B2 (ja) |
BR (1) | BR112014009421A2 (ja) |
CA (1) | CA2852274C (ja) |
GT (1) | GT201400071A (ja) |
IL (2) | IL231987B (ja) |
IN (1) | IN2014KN00796A (ja) |
MX (2) | MX365635B (ja) |
RU (2) | RU2017136415A (ja) |
WO (1) | WO2013059753A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018513185A (ja) * | 2015-04-22 | 2018-05-24 | シン−ナット プロダクツ エンタープライズ エルエルシー | 共結晶組成物及びその医薬用途 |
JP2022001599A (ja) * | 2015-10-05 | 2022-01-06 | ニューカナ パブリック リミテッド カンパニー | 併用療法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102186487B (zh) * | 2008-10-14 | 2013-05-15 | 奈瑞姆生物技术公司 | 提取强心苷的方法和组合物 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070154573A1 (en) * | 2005-12-27 | 2007-07-05 | Juay Jamil Rashan | Method of preparing and using a cold extract from the leaves of nerium oleander |
US20100092585A1 (en) * | 2008-10-14 | 2010-04-15 | Nerium Biotechnology, Inc. | Plant extraction method and compositions |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK239687A (da) | 1986-05-13 | 1987-11-14 | Huseyin Ziya Ozel | Planteekstrakter |
CA2354037A1 (en) | 1998-09-24 | 2000-03-30 | Ozelle Pharmaceuticals, Inc. | Extract of nerium species, pharmaceutical composition thereof and methods for preparation thereof |
US7407675B2 (en) * | 2002-12-27 | 2008-08-05 | The Trustees Of Columbia University In The City Of New York | Anti-neoplastic compositions comprising extracts of black cohosh |
US20060205679A1 (en) * | 2004-10-22 | 2006-09-14 | Azaya Therapeutics, Inc. | Topical and oral formulations of cardiac glycosides for treating skin diseases |
US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
DK2173337T3 (da) | 2007-08-06 | 2014-09-15 | Univ Ohio | Phosphaplatiner og deres anvendelse i behandlingen af cancer, der er resistent over for cisplatin og carboplatin |
-
2012
- 2012-10-20 WO PCT/US2012/061226 patent/WO2013059753A1/en active Application Filing
- 2012-10-20 IN IN796KON2014 patent/IN2014KN00796A/en unknown
- 2012-10-20 CN CN201280051254.5A patent/CN104093405A/zh active Pending
- 2012-10-20 EP EP20159407.4A patent/EP3711754A1/en not_active Withdrawn
- 2012-10-20 CA CA2852274A patent/CA2852274C/en not_active Expired - Fee Related
- 2012-10-20 RU RU2017136415A patent/RU2017136415A/ru not_active Application Discontinuation
- 2012-10-20 MX MX2014004527A patent/MX365635B/es active IP Right Grant
- 2012-10-20 CN CN201910226194.XA patent/CN110269940A/zh active Pending
- 2012-10-20 BR BR112014009421A patent/BR112014009421A2/pt not_active Application Discontinuation
- 2012-10-20 RU RU2014120179/15A patent/RU2014120179A/ru unknown
- 2012-10-20 JP JP2014537346A patent/JP6255346B2/ja not_active Expired - Fee Related
- 2012-10-20 EP EP12841023.0A patent/EP2768498B1/en active Active
- 2012-10-20 AU AU2012325819A patent/AU2012325819B2/en not_active Ceased
-
2013
- 2013-03-15 US US13/838,739 patent/US20130209579A1/en not_active Abandoned
-
2014
- 2014-04-07 IL IL231987A patent/IL231987B/en not_active IP Right Cessation
- 2014-04-14 MX MX2019006685A patent/MX2019006685A/es unknown
- 2014-04-15 GT GT201400071A patent/GT201400071A/es unknown
-
2017
- 2017-10-31 AU AU2017254875A patent/AU2017254875A1/en not_active Abandoned
-
2019
- 2019-05-21 AU AU2019203577A patent/AU2019203577A1/en not_active Abandoned
- 2019-05-22 US US16/419,226 patent/US20190343908A1/en not_active Abandoned
-
2020
- 2020-06-24 IL IL275636A patent/IL275636A/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070154573A1 (en) * | 2005-12-27 | 2007-07-05 | Juay Jamil Rashan | Method of preparing and using a cold extract from the leaves of nerium oleander |
US20100092585A1 (en) * | 2008-10-14 | 2010-04-15 | Nerium Biotechnology, Inc. | Plant extraction method and compositions |
Non-Patent Citations (2)
Title |
---|
INVEST. NEW DRUGS, vol. Vol. 24, JPN6016024067, 2006, pages pp. 423-427 * |
J. NAT. PROD., vol. Vol. 72, JPN6016024066, 2009, pages pp. 1969-1974 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018513185A (ja) * | 2015-04-22 | 2018-05-24 | シン−ナット プロダクツ エンタープライズ エルエルシー | 共結晶組成物及びその医薬用途 |
JP2022001599A (ja) * | 2015-10-05 | 2022-01-06 | ニューカナ パブリック リミテッド カンパニー | 併用療法 |
Also Published As
Publication number | Publication date |
---|---|
WO2013059753A1 (en) | 2013-04-25 |
AU2012325819B2 (en) | 2017-08-03 |
CN110269940A (zh) | 2019-09-24 |
JP6255346B2 (ja) | 2017-12-27 |
IN2014KN00796A (ja) | 2015-10-02 |
NZ623550A (en) | 2016-06-24 |
CA2852274C (en) | 2019-08-06 |
IL231987B (en) | 2020-07-30 |
EP2768498B1 (en) | 2020-03-04 |
CN104093405A (zh) | 2014-10-08 |
AU2019203577A1 (en) | 2019-06-13 |
BR112014009421A2 (pt) | 2017-04-18 |
MX365635B (es) | 2019-06-10 |
IL275636A (en) | 2020-08-31 |
RU2014120179A (ru) | 2015-11-27 |
EP3711754A1 (en) | 2020-09-23 |
MX2019006685A (es) | 2019-08-21 |
US20130209579A1 (en) | 2013-08-15 |
EP2768498A1 (en) | 2014-08-27 |
RU2017136415A3 (ja) | 2021-02-08 |
AU2017254875A1 (en) | 2017-11-23 |
GT201400071A (es) | 2015-09-17 |
CA2852274A1 (en) | 2013-04-25 |
RU2017136415A (ru) | 2019-02-08 |
US20190343908A1 (en) | 2019-11-14 |
AU2012325819A1 (en) | 2014-04-24 |
IL231987A0 (en) | 2014-05-28 |
EP2768498A4 (en) | 2015-06-17 |
MX2014004527A (es) | 2014-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Banerjee et al. | Oxidative stress triggered by naturally occurring flavone apigenin results in senescence and chemotherapeutic effect in human colorectal cancer cells | |
Ellis et al. | A randomized, open-label phase II trial of volasertib as monotherapy and in combination with standard-dose pemetrexed compared with pemetrexed monotherapy in second-line treatment for non–small-cell lung cancer | |
Falk et al. | Bevacizumab: a dose review | |
Xia et al. | Metformin combined with nelfinavir induces SIRT3/mROS-dependent autophagy in human cervical cancer cells and xenograft in nude mice | |
JP2016519076A (ja) | マイクロrna及びegfr−tki阻害剤を利用する癌の併用処置 | |
US20190343908A1 (en) | Therapeutic Combination for the Treatment of Cancer | |
Cillà et al. | Anti-vascular endothelial growth factors protect retinal pigment epithelium cells against oxidation by modulating nitric oxide release and autophagy | |
Peng et al. | Melanoma suppression by quercein is correlated with RIG-I and type I interferon signaling | |
Kim et al. | Imatinib‑induced apoptosis of gastric cancer cells is mediated by endoplasmic reticulum stress | |
Hu et al. | Berbamine enhances the efficacy of gefitinib by suppressing STAT3 signaling in pancreatic cancer cells | |
Wang et al. | XIAOPI formula promotes breast cancer chemosensitivity via inhibiting CXCL1/HMGB1-mediated autophagy | |
Qu et al. | Astragaloside IV enhances cisplatin chemosensitivity in hepatocellular carcinoma by suppressing MRP2 | |
Xia et al. | Synergistic effects of gefitinib and thalidomide treatment on EGFR-TKI-sensitive and-resistant NSCLC | |
Chen et al. | The synthetic flavonoid WYC02-9 inhibits colorectal cancer cell growth through ROS-mediated activation of MAPK14 pathway | |
Früh et al. | Carboplatin and paclitaxel plus ASA404 as first-line chemotherapy for extensive-stage small-cell lung cancer: a multicenter single arm phase II trial (SAKK 15/08) | |
Chung et al. | PI3K inhibitors in trastuzumab-resistant HER2-positive breast cancer cells with PI3K pathway alterations | |
Peng et al. | Dual inhibition of pirarubicin-induced AKT and ERK activations by phenformin sensitively suppresses bladder cancer growth | |
Li et al. | Comparative effectiveness of pemetrexed-platinum doublet chemotherapy with or without bevacizumab as first-line therapy for treatment-naive patients with advanced nonsquamous non–small-cell lung cancer in China | |
Chen et al. | Guggulsterone induces apoptosis and inhibits lysosomal-dependent migration in human bladder cancer cells | |
Tian et al. | The Nrf2 inhibitor brusatol synergistically enhances the cytotoxic effect of lapatinib in HER2-positive cancers | |
Zhang et al. | Preclinical evaluation of the dual mTORC1/2 inhibitor sapanisertib in combination with cisplatin in nasopharyngeal carcinoma | |
Cheng et al. | Metformin synergistically enhances the antitumour activity of Lenvatinib in hepatocellular carcinoma by altering AKT‐FOXO3 signalling pathway | |
Qu et al. | Pomiferin targets SERCA, mTOR, and P-gp to induce autophagic cell death in apoptosis-resistant cancer cells, and reverses the MDR phenotype in cisplatin-resistant tumors in vivo | |
Pang et al. | Ethyl ferulate suppresses esophageal squamous cell carcinoma tumor growth through inhibiting the mTOR signaling pathway | |
Kim et al. | β-Apopicropodophyllin functions as a radiosensitizer targeting ER stress in non-small cell lung cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20151001 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160628 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160923 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161228 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170411 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170705 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20171114 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20171204 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6255346 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |